Vivos Inc. has successfully completed a significant stock offering, raising $1 million through the issuance of 12.5 million shares. This move is crucial for the company as it seeks to enhance its financial stability and support ongoing operational needs.

The announcement was made in a recent filing with the Securities and Exchange Commission, detailing the completion of the sale and issuance of common stock under Regulation A+. The funds raised will be allocated for general working capital purposes, which may help the company advance its strategic initiatives in the surgical and medical instruments sector.

Background

Vivos Inc., incorporated in Delaware, operates in the surgical and medical instruments and apparatus industry, classified under SIC code 3841. The company trades on the OTC exchange under the ticker symbol RDGL. Recent filings indicate that Vivos has been actively engaging with investors and exploring various funding mechanisms to support its growth.

What the Filing Says

According to the filing dated November 5, 2026, Vivos completed the sale of 12.5 million shares on October 30, 2026, resulting in gross proceeds of $1 million. The filing states, "The Offering resulted in gross proceeds to the Company of $1,000,000. Proceeds from the sale of Common Stock in connection with the Offering will be used for general working capital purposes." This strategic move is expected to provide Vivos with the necessary capital to enhance its operations.

Impact

This stock offering may significantly affect Vivos Inc. by providing the necessary funds to support its operational growth and financial health. Additionally, it could influence investor sentiment in the surgical and medical instruments industry, as other companies may consider similar funding strategies to bolster their financial positions.

What's Next

Looking ahead, Vivos Inc. has scheduled its 2026 Annual Meeting of Stockholders for December 9, 2026. The company has set a record date of November 2, 2026, for stockholders to participate in the meeting. Shareholders who wish to submit proposals for consideration at the meeting must do so by November 9, 2026. The company has indicated that further details regarding the matters to be voted on will be provided in the proxy statement to be filed with the SEC prior to the meeting.